| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 260 | 120 | 3,100 | 700 |
| Sales Growth | -100.00% | +116.67% | -96.13% | +342.86% | -37.50% |
| Net Income | -27,520 | -19,030 | -18,050 | -14,790 | -2,850 |
| Net Income Growth | -44.61% | -5.43% | -22.04% | -418.95% | +50.17% |
Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Inhibikase Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing therapeutics for Parkinson's disease and related disorders. The company operates principally in Boston, Massachusetts. Inhibikase Therapeutics Inc. is headquartered in Atlanta, Georgia.
Fiscal Year End Date: 12/31